• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Patient-reported outcome assessment of inflammatory arthritis patient experience with intravenously administered biologic therapy
【24h】

Patient-reported outcome assessment of inflammatory arthritis patient experience with intravenously administered biologic therapy

机译：静脉注射生物疗法的炎症性关节炎患者经验的患者报告结局评估

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: To evaluate patient perspectives regarding utilization of intravenous (IV) therapy for inflammatory arthritis (IA). Methods: This was a single-center, noninterventional, patient questionnaire-based study of adult IA patients currently receiving IV biologics. At a single visit, patients completed the questionnaire comprising 30 questions centered on their experience receiving an intravenously administered therapy to treat their IA. The questionnaire included questions on patient demographics, disease characteristics, and previous biologic treatment for IA (subcutaneous [SC] and IV). Patients rated their level of agreement with statements regarding satisfaction with current IV biologic therapy and potential advantages and disadvantages of IV biologic therapy using a 5-point Likert scale (1=?strongly disagree, 5=?strongly agree). Results: One hundred patients were enrolled and completed the survey; 66% were female and the mean age was 58 years. Before IV treatment, 97% of patients received information regarding therapy options. Ninety patients ranked their satisfaction with current IV therapy as 4 or 5. The proportion of patients with an “extremely favorable” perception of IV therapy increased from 33% to 71% following initiation of their current medication. Thirty-one patients had previously received SC therapies to treat their IA. Conclusion: These results demonstrated an overall favorable perception of IV therapy among this patient population. Patients previously treated with SC therapy also had a positive shift in the perception of IV therapy after initiating IV therapy. Patients’ perception and preference for treatment options should be highly considered by the treating physician during or as part of a shared decision-making process.
机译：目的：评估患者对利用静脉（IV）治疗炎性关节炎（IA）的观点。方法：这是一项单中心，非干预，基于患者问卷的研究，研究对象是目前正在接受静脉内生物制剂治疗的成年IA患者。在单次就诊时，患者填写了包含30个问题的问卷，这些问题集中于他们接受静脉注射治疗IA的经历。问卷包括有关患者的人口统计学，疾病特征和先前对IA的生物治疗（皮下[SC]和IV）的问题。患者使用五点李克特量表（1 =强烈不同意，5 =强烈同意），对有关对当前IV生物疗法的满意度以及IV生物疗法的潜在优势和劣势的陈述对自己的同意水平进行评分。结果：纳入了100名患者并完成了调查。 66％为女性，平均年龄为58岁。在进行IV治疗之前，有97％的患者获得了有关治疗选择的信息。 90名患者对目前的IV治疗的满意度为4或5。在开始使用当前药物后，对IV治疗有“极佳”感觉的患者比例从33％增加到71％​​。先前有31名患者接受了SC治疗来治疗他们的IA。结论：这些结果表明，该患者人群对静脉疗法的总体认知良好。在开始静脉治疗后，先前接受SC治疗的患者对静脉治疗的认知也发生了积极变化。在共享决策过程中或作为共享决策过程的一部分，主治医生应高度考虑患者对治疗方案的看法和偏好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号